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HbA1c 6.5% has recently been recommended as an alternative diagnostic criterion for diabetes. e aims of the study were to
evaluate the effects of age, sex, and other factors on prevalence of diabetes and to compare risk pro�les of subjects with diabetes
when de�ned by HbA1c and glucose criteria. Subjects were recruited among participants in the longitudinal population-based
Tromsø Study. HbA1c, fasting plasma glucose, and 2-hour plasma glucose were measured in 3,476 subjects. In total, 294 subjects
met one or more of the diagnostic criteria for diabetes; 95 met the HbA1c criterion only, 130 met the glucose criteria only, and 69
met both. Among subjects with diabetes detected by glucose criteria (regardless of HbA1c), isolated raised 2-hour plasma glucose
was more common in subjects aged ≥ 60 years as compared to younger subjects and in elderly women as compared to elderly men.
Subjects with diabetes detected by glucose criteria only had worse cardiometabolic risk pro�les than those detected by HbA1c only.
In conclusion, the current HbA1c and glucose criteria de�ned different subjects with diabetes with only modest overlap. Among a
substantial proportion of elderly subjects, and especially elderly women, the 2-hour plasma glucose was the only abnormal value.
1. Introduction
Criteria for the diagnosis of diabetes are based on mea-
surements of fasting plasma glucose (FPG), 2-hour plasma
glucose (2hPG), or haemoglobin A1c (HbA1c). Single raised
values with symptoms or raised values on two occasions of
any one of these tests, or a combination of these tests can
be used for diagnosis of diabetes [1, 2]. e most commonly
used test is the FPG as it is simple and inexpensive. e
2hPG is measured in combination with FPG in the oral
glucose tolerance test (OGTT), where plasma glucose is
measured in the morning aer an overnight fast and 2
hours aer oral ingestion of 75 g glucose. HbA1c was recently
introduced as a diagnostic test for diabetes. Compared to
glucose measurements, HbA1c has better sample stability,
lower within-person variation and is independent of acute
factors such as illness, recent food ingestion, stress, or exercise
[3].
Diagnostic levels of FPG, 2hPG, and HbA1c are based on
thresholds for increased risk of micro- and macrovascular
disease, in particular retinopathy [1, 4]. In the DETECT-2
study, sensitivity and speci�city for prediction of prevalent
retinopathy were almost equal when comparing FPG, 2hPG
and HbA1c [5]. Several recent studies have shown that both
the prevalence of diabetes and the subjects diagnosed with
diabetes vary when different diagnostic criteria for diabetes
are applied [6–11]. According to current guidelines, clinicians
can choose freely among FPG, OGTT, and HbA1c when
testing a patient for diabetes [1, 2]. As HbA1c and glucose
criteria have been shown to identify different subjects with
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diabetes with relativelymodest overlap, the choice of test may
affect the test outcome [6, 7, 9]. is is important both at
the individual level, where correct diagnosis, treatment, and
prevention of later complications are in focus, and at the
population level where early identi�cation of the “correct”
individuals at risk of developing complications is important
for cost-effective utilisation of resources. Furthermore, race,
age, and sex have been reported to affect the outcome
of diabetes testing with different diagnostic criteria [6–
8, 12, 13]. is could have implications for the preferred
choice of test in subgroups of patients. In Tromsø we have
recently performed a large health survey where we measured
HbA1c, FPG, and 2hPG in 3,476 subjects without previously
diagnosed diabetes. ese data enabled us to study the
effect of age, sex, and other factors on diabetes de�ned by
different diagnostic criteria and to compare cardiometabolic
risk pro�les of subjects with diabetes de�ned by different
criteria.
2. Materials andMethods
2.1. Subjects. Subjects were recruited from the sixth survey of
the longitudinal population-based Tromsø Study performed
by the University of Tromsø from October 2007 to December
2008, where HbA1c was measured in 12,769 participants. All
subjects without self-reported diabetes and with HbA1c in
the range 5.8–6.9% and a random sample of approximately
200 subjects with HbA1c 5.3% and 5.4% and 100 subjects
with HbA1c 5.5%, 5.6%, and 5.7%, respectively, were invited
to participate in the Tromsø OGTT Study. Race was not
registered, but practically all subjects were Caucasian.
2.2. Measurements. Waist and hip circumference, height,
weight, and blood pressure were measured, body mass index
(BMI) was de�ned, and physical activity score (PAS) was cal-
culated as previously described [14]. HbA1c was determined
by high performance liquid chromatography (HPLC) using
an automated analyser (Variant II, Bio-Rad Laboratories Inc.,
Hercules, CA, USA). e reference interval was 4.3–6.1%.
is analysis has been certi�ed by the National Glycohe-
moglobin Standardization Program (NGSP) as having doc-
umented traceability to the Diabetes Control and Compli-
cation Trial (DCCT) reference method [15]. Haemoglobin
(Hb) was measured by photometry using an automated
analyser (reference intervals 11.5–16.0 g/dL for women and
13.0–17.0 g/dL for men). Plasma glucose, serum insulin, and
serum C-peptide were measured and analysed as previously
described [14]. Serum triglyceride (TG) was analysed with
an enzymatic colorimetric assay using an automated clinical
chemistry analyser (reference interval 0.5–2.6mmol/L). Esti-
mates of insulin sensitivity in the fasting state were calculated
using homeostasis model assessment (HOMA-IR) and the
Quantitative Insulin-Sensitivity Check Index (QUICKI) [16,
17], and insulin sensitivity including the 2-hour values for
glucose and insulinwith the insulin sensitivity index (ISI0.120)
according to the formula by Gutt et al. [(𝑚𝑚/MPG)/log MSI,
where 𝑚𝑚 = (75 000mg + [fasting glucose (mg/dL) − 2-
h glucose (mg/dL)] × 0.19 × body weight (kg))/120min,
MPG = mean of fasting and 2-h glucose concentrations
(mmol/L); MSI = mean of fasting and 2-h insulin concentra-
tions (milliunits per liter)] [18].
OGTTswere performed fromFebruary 2008 until August
2010 as previously described [14]. All OGTTs were per-
formed in the morning aer an overnight fast. To min-
imize time between OGTT and HbA1c, the latter was
measured simultaneously with the OGTT from September
2008 onwards. HbA1c from the Tromsø Study 2007-2008
was used for the 932 participants who completed OGTT
before September 2008. Mean change in HbA1c for the
2,544 subjects who measured HbA1c on both occasions was
−0.03 ± 0.3%. For the purpose of this study, we chose to
classify subjects with a single value of FPG ≥ 7.0mmol/L,
2hPG ≥ 11.1mmol/L, and/or HbA1c ≥ 6.5% as having
diabetes, even though subjects were asymptomatic. Subjects
with diabetes were subdivided into diabetes detected by
HbA1c only, byOGTT (raised FPG and/or 2hPG) only and by
both. Furthermore, subjects with diabetes detected by OGTT
(regardless of HbA1c) were subdivided into diabetes detected
by FPG (regardless of 2hPG) and by isolated raised 2hPG.
2.3. Statistics. Normal distribution was evaluated by visual
inspection of histograms and determination of skewness and
kurtosis, and aer natural log transformation of TG, PAS,
QUICKI, HOMA-IR, and ISI0.120, all variables except the
PAS (where several subjects had “0” values) were consid-
ered normally distributed. Ln values were used when these
variables were dependent variables. Pearson Chi-square test
was used for subgroup analysis in Table 2. Comparisons
between groups were performed with logistic regression for
categorical variables and univariate analysis of variance with
Bonferroni post hoc adjustment or Mann Whitney U test
for continuous variables in Table 3. Venn diagrams were
constructed to illustrate overlap between diagnostic criteria
and scatterplots to illustrate the distribution of FPG and
2hPG values in relation to HbA1c. Unless otherwise stated,
data are expressed as mean ± SD for normally distributed
values and as median (5, 95 percentile) for non-normally
distributed values. All tests were two-sided, and 𝑃𝑃 value <
0.05 was considered statistically signi�cant. e Statistical
Package for Social Sciences version 17.0 was used for all
statistical analyses (SPSS Inc., Chicago, IL, USA).
3. Results
Among the 4,393 subjects who were invited, 3,520 attended
and 3,476 completed the OGTT. e number of subjects
planned to participate, invited to OGTT, and attended at
different HbA1c levels, as measured in the Tromsø Study
2007-2008, is presented in Table 1. In total, 294 (8.5%)
subjects met one or more of the diagnostic criteria for
diabetes. Mean age was 61 years and 49.5% were women.
3.1. �re�a�ence �� �iabetes �e�ne� b� �i�erent �ia�n�stic
Criteria. Among those who completed OGTT, 164 (4.7%)
met the HbA1c criterion, 119 (3.4%) met the FPG criterion,
and 126 (3.6%) met the 2hPG criterion. In total 199 (5.7%)
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T 1: Number of participants planned to participate, invited to participate, attended, and completed OGTT in the Tromsø OGTT Study.
HbA1c level in the sixth Tromsø Number of subjects
study survey (2007-2008) Planned to participate Invited to participate Attended OGTT Completed OGTT
5.3% 200 309 180 176
5.4% 200 308 195 194
5.5% 100 144 109 107
5.6% 100 164 128 123
5.7% 100 157 115 112
5.8–6.9% All 3311 2793 2764
Total 4393 3520 3476
Abbreviations: Haemoglobin A1c, HbA1c; oral glucose tolerance test, OGTT.
e table summarises how many subjects were planned to participate in the OGTT Study, how many were invited to OGTT, how many attended, and how
many who completed OGTT at different HbA1c levels and in total.
met the OGTT (FPG and/or 2hPG) criteria. As presented in
Table 2, 95 (32.3%) of those with diabetes met the HbA1c
criterion only, 130 (44.2%) met the OGTT criteria only, and
69 (23.5%) met both criteria. e overlap between subjects
with diabetes de�ned by HbA1c and OGTT varied between
10–35% in different subgroups.
HbA1c alone detected more subjects with diabetes as
compared to OGTT alone in those with BMI < 25 kg/m2, TG
< 1.2mmol/�, and high PAS, but there were no signi�cant
differences in subgroup analysis of age and sex (Table 2).
Among those with diabetes detected by OGTT (regardless of
HbA1c), isolated raised 2hPG was more common in subjects
aged ≥ 60 years and women (Table 2). is effect of age and
sex was not due to differences in BMI. Strati�cation for age
showed that the sex difference was signi�cant only in those
aged ≥ 60 years, where 58% of women and 36% of men had
isolated raised 2hPG (𝑃𝑃 < 𝑃𝑃𝑃1). Mean age and BMI did not
differ signi�cantly between men and women. Furthermore,
the sex difference was signi�cant only in the two lower BMI
groups (𝑃𝑃 < 𝑃𝑃𝑃𝑃) and in the lowest PAS tertile (𝑃𝑃 < 𝑃𝑃𝑃𝑃).
e distribution of subjects with diabetes detected by
HbA1c only, OGTT only, and both, as well as by OGTT
components (FPG and isolated raised 2hPG) is illustrated
strati�ed for age and sex in Figure 1. e overlap between
subjects with diabetes de�ned by HbA1c and OGTT was
relatively consistent, but prevalence of isolated raised 2hPG
was higher in subjects aged ≥ 60 years as compared to
younger subjects, and in elderly women as compared to
elderly men. In subjects aged ≥ 60 years the distribution of
2hPG values in relation to HbA1c values was more scattered
as compared to younger subjects (Figure 2), illustrating that
formany subjects in this age group anHbA1c value< 6.5% did
not exclude a 2hPG value above the cut off point for diabetes.
�.�. C�aracteristics o� ����ects �it�Dia�etes De�ne� ��Di�er�
ent Diagnostic Criteria. As presented in Table 3, subjects with
diabetes detected byHbA1c only had lower TG, lower systolic
blood pressure, higher insulin sensitivity andwere less insulin
resistant and more physically active as compared to subjects
with diabetes detected by OGTT only. Among subjects with
diabetes detected by OGTT (regardless of HbA1c), those with
raised FPG differed from those with isolated raised 2hPG
by being younger, predominantly men and more insulin
resistant (Table 3).
4. Discussion
�.�. �re�a�ence o� Dia�etes De�ne� �� Di�erent Diagnostic
Criteria. In our population, we found prevalence of diabetes
detected by OGTT only to be higher than prevalence of
diabetes detected by HbA1c only. e present study also con-
�rmed results from recent studies showing that HbA1c and
OGTT de�ne different subjects with diabetes with relatively
modest overlap, which in our study was only 23.5% [6, 7, 9].
Prevalence of diabetes de�ned by HbA1c and OGTT, and
overlap between these, differs in previous studies, probably
due to differences in age, race, and sex composition of the
populations and/or lack of standardisation of HbA1c and
glucose measurements [7, 8, 12, 13, 19].
Race, age, and sex have been reported to affect the
outcome of diabetes testing with different diagnostic criteria
[6–8, 12, 13]. Our study population did not allow us to study
the effect of race as practically all subjects were Caucasian.
When comparing subjects aged ≥ 60 years with younger
subjects, we found no difference in prevalence of diabetes
detected by HbA1c only and OGTT only. Among those with
diabetes detected byOGTT (regardless ofHbA1c), prevalence
of isolated raised 2hPG was higher in older (≥60 years) as
compared to younger subjects. Furthermore, we found that
among subjects aged≥ 60 years, having a 2hPG in the diabetic
range but a nondiabetic HbA1c value was more common
as compared to younger subjects. Similarly, in the Finnish
population-based cross sectional FIN-D2D study including
2,826 men and women aged 45–74 years, any given HbA1c
value was found to imply a much higher 2hPG and slightly
lower FPG in elderly as compared to middle aged subjects
[13]. e 2hPG is known to increase more with age than FPG
[20, 21]. Possible explanations for the increased prevalence of
isolated raised 2hPG among elderly subjects could be reduced
basal insulin secretion [22], delayed insulin response aer
oral glucose intake [21], physical inactivity, and/or weight
gain [23].
In our data, there was no sex difference in diabetes
detected by HbA1c only and OGTT only. However, we found














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































F 1: Diabetes prevalence by different diagnostic criteria. Venn diagrams illustrating prevalence of diabetes (%) de�ned byOGTT criteria
(FPG and isolated raised 2hPG) and HbA1c in (a) men aged < 60 years; (b) men aged ≥ 60 years; (c) women aged < 60 years; (d) women ≥ 60
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F 2: Distribution of FPG and 2hPG values in relation to HbA1c. Scatterplots illustrating the distribution of (a) FPG and (b) 2hPG values
in relation to HbA1c in subjects aged < 60 years and subjects aged ≥ 60 years. Stippled lines show cut-off points for diabetes. e Tromsø
OGTT Study.
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that among those with diabetes detected by OGTT (regard-
less of HbA1c), isolated raised 2hPG was more common in
elderly women as compared to elderly men, a difference that
could not be explained by differences in age or BMI. Similarly,
the FIN-D2D study reported that HbA1c tends to miss more
elderly diabetic people and especially women [13]. Previous
studies have suggested that differences in FPG and HbA1c
levels are likely to re�ect sex-speci�c differences in glucose
regulation as they, unlike differences in 2hPG, remained
aer adjusting for height and body composition [24, 25]. We
also found that HbA1c alone detected more subjects with
diabetes as compared to OGTT alone in subjects with BMI
< 25 kg/m2 as compared to those with higher BMI. In a
recently published paper, we reported that a particular HbA1c
value implied relatively higher 2hPG and FPG in subjects
with high BMI compared to subjects with lower BMI [14].
As very few reports have addressed this issue, it remains
uncertain whether BMI has an effect on diagnosis of diabetes
by different criteria.
�.�. C�aracteristics of ����ects �it� Dia�etes De�ne� �� Dif�
ferent Diagnostic Criteria. In our population, subjects with
diabetes detected byOGTTonly had aworse cardiometabolic
risk pro�le than those detected by HbA1c only. Previous
studies have shown con�icting results� some have found
the worst risk pro�les in subjects with diabetes de�ned by
OGTT [6, 8, 9], some in subjects with diabetes de�ned by
HbA1c [26], and some have found the two groups to have
equally unfavourable risk pro�les [8, 10]. In the international
A1C-Derived Average Glucose study including 427 subjects
with diabetes, HbA1c, FPG, and 2hPG were all associated
with CVD risk factors, but the strongest association was
seen with HbA1c [27]. We did not have data to evaluate
the risk of diabetes complications in the different groups.
Although both HbA1c and 2hPG have been shown to be
independent risk factors for cardiovascular morbidity and
mortality, the added prognostic informationmay bemarginal
as compared to standard nonglycaemic risk factors [28–30].
In a prospective study based on the Norwegian population-
based longitudinal HUNT study, the risk of macrovascular
complications in subjects with relatively low HbA1c values
was found to be mainly related to conventional risk factors
[31].
e strength of our study is that OGTT was performed
in a large number of subjects recruited from a population
representative of the general population in our area.emain
shortcomings of our study are that only subjects with HbA1c
in the range of 5.3–6.9% were invited to participate and that
subjects included at an early stage of the study did not have
HbA1c measured simultaneously with the OGTT, but were
included in the analysis with theHbA1c valuemeasured in the
Tromsø Study 2007-2008. We chose to include these subjects
in the analysis as we found that change in HbA1c from the
Tromsø Study to the OGTT visit was negligible for those
who hadHbA1c measured at both occasions. Furthermore, in
the absence of clear symptoms, diagnosis of diabetes requires
raised values of HbA1c, FPG, or 2hPG on two occasions.
For practical reasons, we did not repeat either HbA1c, or the
OGTTs, but chose to classify subjects with a single raised
value of HbA1c, FPG, or 2hPG as having diabetes. As FPG,
and especially 2hPG, are known to have high within-person
variation, repeating the OGTTs to con�rm the diagnosis
would probably have reduced the number of subjects with
diabetes detected by OGTT [32]. HbA1c is known to be
affected by anaemia. Hb was measured in the Tromsø Study
2007-2008, but not simultaneously as OGTT. However,
anaemia is not a source of error when analysing HbA1c with
the HPLC method used in our study as the analysis is not
performed if there are too few or too many erythrocytes in
the sample. Haemolytic anaemia could result in falsely low
HbA1c, but the condition is rare in our population and is not
likely to affect the results. Other shortcomings are that we did
not have information about retinopathy or other end organ
diseases, and that we did not differentiate between type 1 and
type 2 diabetes. However, as subjects in our study did not have
previously diagnosed diabetes and age ranged from 30–87
years, most diabetes cases were likely to be type 2 diabetes.
e cross-sectional study design is a major limitation when
evaluating the impact of using different diagnostic criteria
for diabetes. Prospective studies are needed to clarify which
test detects the population with the highest risk of disease
progression and complications of diabetes.
5. Conclusions
e current HbA1c and glucose criteria for diabetes de�ned
different subjects with only modest overlap. Among those
with diabetes detected by OGTT (regardless of HbA1c),
isolated raised 2-hour plasma glucose was more common in
subjects aged ≥ 60 years as compared to younger subjects,
and in elderly women as compared to elderly men. As race,
age, sex, and possibly BMI seem to affect HbA1c, FPG,
and 2hPG and the relationship between these, creating an
algorithm for choice of diagnostic test in different subgroups
is a possibility and may be bene�cial. If the aim is to detect
as many patients with diabetes as possible, our data suggest
that OGTTwould be preferable for those aged≥ 60 years, and
especially women, while HbA1c would be preferable for the
younger and those with low BMI. However, in order to decide
which diagnostic test should be preferred, and whether race,
age, sex, and/or BMI speci�c guidelines should be considered,





OGTT: Oral glucose tolerance test
FPG: Fasting plasma glucose
2hPG: 2-hour plasma glucose
HPLC: High precision liquid chromatography
BMI: Body mass index
HOMA-IR: Homeostasis model assessment-insulin
resistance
QUICKI: Quantitative insulin-sensitivity check
index
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ISI0.120: Insulin sensitivity index,
PAS: Physical activity score
TG: Triglycerides.
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